PATENT CLAIM ANALYSIS

Application Number: 16042833
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "04400A"]

Abstract:
In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

Claim (Index 31):
A method of treating AMD in a subject comprising administering to the subject an RNA duplex of an antisense strand of at least 19 nucleotides (nt) in length and a sense strand of 16 nt in length, wherein:\n the sequence of the antisense strand comprises SEQ ID NO: 54 or SEQ ID NO: 56; the sequence of the sense strand is SEQ ID NO: 53 or SEQ ID NO: 55; a cholesterol moiety is attached to the 3\u2032 end of the sense strand; and the antisense strand and the sense strand form a complex in which the 5\u2032 end of the antisense strand and the 3\u2032 end of the sense strand form a blunt end.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.54762
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15352322', '15220767', '15422122', '15422186', '15483305']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7686557735436741
- 35 USC 102 Novelty (BERT): 0.6839148322649542
- Combined Prediction Score: 0.7601816794158022
- Mean Citation Score: 487.25584
- Max Citation Score: 738.3603
- Similarity Product: 657.4455556628109

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test